Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

High Ki67 Index Is Associated with Shorter Progression Free Survival in Follicular Lymphoma Patients Treated with Frontline Immunochemotherapy

Jianmin Han, Chad M McCall, Scott Isom, Wesley Smith, Dakota Jenneman, Stephanie Begley, Rupali Bose, Mary Beth Seegars, Eric D. Hsi, Nilanjan Ghosh

Blood (2023) 142 (Supplement 1): 4385.

https://doi.org/10.1182/blood-2023-180106

Published: 2023

Journal Articles

Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

Rao Mushtaq, MD, Faisal Akbar, MBBS, MD, Israa Khan, MD, Scott Isom, M.S., Timothy Pardee, MD PhD, Dianna S. Howard, MD, Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2018-99-110191

Published: 2018

Journal Articles

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Timothy Pardee, MDPhD, Scott Isom, M.S., Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2018-99-118991

Published: 2018

Journal Articles

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Timothy S Pardee, MD PhD, Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2017) 130 (Supplement 1): 2626.

https://doi.org/10.1182/blood.V130.Suppl_1.2626.2626

Published: 2017

Journal Articles

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

Margaux Wooster, B.S., Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Megan Manuel, M.S.N, Rupali Bhave, MD, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD, Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 5044.

https://doi.org/10.1182/blood.V130.Suppl_1.5044.5044

Published: 2017

Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2016) 128 (22): 4062.

https://doi.org/10.1182/blood.V128.22.4062.4062

Published: 2016

Journal Articles

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Zanetta S. Lamar, MD, Scott Isom, MS, Rakhee Vaidya, MD, Anne W Beaven, MD, Zachariah A. McIver, DO

Blood (2016) 128 (22): 4163.

https://doi.org/10.1182/blood.V128.22.4163.4163

Published: 2016

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2015) 126 (23): 2556.

https://doi.org/10.1182/blood.V126.23.2556.2556

Published: 2015

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2014) 124 (21): 3744.

https://doi.org/10.1182/blood.V124.21.3744.3744

Published: 2014

Journal Articles

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

Tamjeed Ahmed, MD, Scott Holwerda, MD, Timothy Pardee, MD, PhD, Scott Isom, MS, Susan Lyerly, PA, Leslie Renee Ellis, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Berenzon Dmitriy, MD, Heidi D. Klepin, MD, MS, Bayard L. Powell, MD

Blood (2013) 122 (21): 2700.

https://doi.org/10.1182/blood.V122.21.2700.2700

Published: 2013

Journal Articles

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Timothy Pardee, MD, PhD, King Lee, PhD, RAC, John Luddy, MS, Claudia Maturo, MS, Robert Rodriguez, BSc, MBA, Denise A Levitan, MD, David D Hurd, MD, Leslie Renee Ellis, MD, Scott Isom, MS, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2013) 122 (21): 486.

https://doi.org/10.1182/blood.V122.21.486.486

Published: 2013

Journal Articles

A Single Institution Analysis of Incidence of Recurrent Chromosomal Abnormalities in Adult ALL Patients According to Race, Gender, and Age

Victoria Chiou, MD, Jacob Tiegs, MD, Scott Isom, MS, Mark J. Pettenati, PhD, Susan Lyerly, PA, Leslie R. Ellis, MD, Timothy Pardee, MD, PhD, Berenzon Dmitriy, MD, Bayard L. Powell, MD, Denise A Levitan, MD

Blood (2011) 118 (21): 4869.

https://doi.org/10.1182/blood.V118.21.4869.4869

Published: 2011

Journal Articles

Geriatric Assessment Predicts Overall Survival Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.

Heidi D. Klepin, MD, MS, Janet A. Tooze, PhD, Ann M. Geiger, PhD, Stephen Kritchevsky, PhD, Jeff Williamson, MD, MHS, Leslie R. Ellis, MD, Denise Levitan, MD, Timothy Pardee, MD, PhD, Scott Isom, MS, Bayard L. Powell, MD

Blood (2010) 116 (21): 1535.

https://doi.org/10.1182/blood.V116.21.1535.1535

Published: 2010

Journal Articles

Inpatient Geriatric Assessment Detects Impairment Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.

Heidi D Klepin, MD, MS, Ann M Geiger, PhD, Jeff Williamson, MD, MHS, Stephen Kritchevsky, PhD, Janet A Tooze, PhD, Leslie Renee Ellis, MD, Denise Levitan, MD, Scott Isom, MS, Bayard L. Powell, MD

Blood (2009) 114 (22): 1401.

https://doi.org/10.1182/blood.V114.22.1401.1401

Published: 2009

NARROW

High Ki67 Index Is Associated with Shorter Progression Free Survival in Follicular Lymphoma Patients Treated with Frontline Immunochemotherapy

Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

A Single Institution Analysis of Incidence of Recurrent Chromosomal Abnormalities in Adult ALL Patients According to Race, Gender, and Age

Geriatric Assessment Predicts Overall Survival Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.

Inpatient Geriatric Assessment Detects Impairment Among Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only